arrow
B

Bianca Santomasso

Memorial Sloan Kettering Cancer Center
H指数:36
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ataxia and Balance Disorders Associated with GPRC5D-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Case Series with Practical Recommendations for Management

共济失调和平衡障碍与GPRC5D靶向疗法在复发/难治性多发性骨髓瘤中的关联:一份病例系列及管理实用建议

2026-10-270
OAAI
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

在多发性骨髓瘤患者中,强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关(cilta-cel治疗)

2026-07-290
PRE
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9作为一种新型预后标志物,用于识别患有噬血细胞性淋巴组织细胞增多症的成人高风险群体。

Blood
IF23.1
2026-02-263
PRE
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4

在CARTITUDE-1、-2和-4研究中,接受ciltacabtagene autoleucel输注治疗复发/难治性MM患者的颅神经麻痹临床经验。

2025-11-260
OAAI
Phase 2 study of amivantamab plus lazertinib in previously-treated patients with EGFR mutant lung cancers with brain and leptomeningeal metastases

II期研究:评估amivantamab联合lazertinib在既往经治的EGFR突变型肺癌伴脑和软脑膜转移患者中的疗效

2025-10-230
PRE
Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma

多中心篮式试验针对中枢神经系统肿瘤,确定了CDK4/6抑制剂abemaciclib在复发性脑膜瘤中的活性

2025-10-010
PRE
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors

胶质瘤和神经胶质神经元肿瘤患者胚系变异的前瞻性表征

2025-09-120
OAAI
PROSPECTIVE GERMLINE SEQUENCING OF PATIENTS WITH GLIOMAS, GLIONEURONAL OR NEURONAL TUMORS
2024-11-110
PRE
Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

免疫治疗相关毒性的管理,2.2024版以NCCN指南的更新为特色

2024-11-010
PRE
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results

CD19 CAR T细胞治疗和预防性anakinra治疗复发或难治性淋巴瘤: 2期试验中期结果

2023-07-0363
PRE
GPRC5D-Targeted CAR T Cells for Myeloma

GPRC5D-Targeted CAR T细胞治疗骨髓瘤

2022-09-29212
OA
Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force

为了更好地了解慢性移植物抗宿主病的非典型特征: 2020国立卫生研究院共识项目工作组的报告

2022-08-0130
OAAI
Management of Immunotherapy-Related Toxicities, Version 1.2022

免疫疗法相关毒性的管理,1.2022版

2022-04-01226
OA
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

CARTITUDE研究中使用ciltacabtagene autoleucel治疗的多发性骨髓瘤患者car-t神经毒性的发生率和管理

2022-02-24128
OAAI
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
2021-10-0158
OAAI
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

修饰的EASIX预测嵌合抗原受体T细胞后严重的细胞因子释放综合征和神经毒性

2021-09-0784
OA
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

免疫检查点抑制剂的神经系统免疫相关不良事件的共识疾病定义

2021-07-19105
OAAI